- Home
- JMM vs AVTX Comparison
JMM vs AVTX Comparison
Compare JMM & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JMM
- AVTX
- Stock Information
- Founded
- JMM 1988
- AVTX 2011
- Country
- JMM United States
- AVTX United States
- Employees
- JMM N/A
- AVTX N/A
- Industry
- JMM Trusts Except Educational Religious and Charitable
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- JMM Finance
- AVTX Health Care
- Exchange
- JMM Nasdaq
- AVTX Nasdaq
- Market Cap
- JMM 58.5M
- AVTX 57.4M
- IPO Year
- JMM N/A
- AVTX 2015
- Fundamental
- Price
- JMM $6.19
- AVTX $4.73
- Analyst Decision
- JMM
- AVTX Strong Buy
- Analyst Count
- JMM 0
- AVTX 7
- Target Price
- JMM N/A
- AVTX $31.00
- AVG Volume (30 Days)
- JMM 16.1K
- AVTX 89.2K
- Earning Date
- JMM 01-01-0001
- AVTX 08-11-2025
- Dividend Yield
- JMM 5.44%
- AVTX N/A
- EPS Growth
- JMM N/A
- AVTX N/A
- EPS
- JMM N/A
- AVTX N/A
- Revenue
- JMM N/A
- AVTX $441,000.00
- Revenue This Year
- JMM N/A
- AVTX N/A
- Revenue Next Year
- JMM N/A
- AVTX N/A
- P/E Ratio
- JMM N/A
- AVTX $0.69
- Revenue Growth
- JMM N/A
- AVTX N/A
- 52 Week Low
- JMM $5.29
- AVTX $3.39
- 52 Week High
- JMM $6.10
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- JMM 50.23
- AVTX 57.87
- Support Level
- JMM $6.06
- AVTX $4.46
- Resistance Level
- JMM $6.27
- AVTX $4.90
- Average True Range (ATR)
- JMM 0.09
- AVTX 0.37
- MACD
- JMM -0.01
- AVTX 0.09
- Stochastic Oscillator
- JMM 54.55
- AVTX 88.61
About JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities including, but not limited to residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).